







# Psoriasis Biosimilar Market Size, Share, Growth, Opportunities, and Regional Forecast to 2032

## Psoriasis Biosimilar Market Overview

The [Psoriasis Biosimilar Market](#) represents a growing segment within the global dermatology and biosimilar industries, driven by increasing demand for cost-effective treatments for psoriasis. Psoriasis, a chronic autoimmune disease that results in the rapid turnover of skin cells, can significantly affect patients' quality of life. Traditional biologic treatments, such as tumor necrosis factor (TNF) inhibitors, interleukin inhibitors, and other monoclonal antibodies, have proven effective for psoriasis management. However, the high costs of these biologics have prompted the development of biosimilars, which are designed to replicate the efficacy, safety, and quality of reference biologics but at a lower price. The entry of biosimilars into the psoriasis market has led to increased treatment access and improved affordability, making it an attractive option for healthcare systems and patients alike.

---

## Market Size and Share

The Psoriasis Biosimilar Market was valued at approximately USD 5 billion in 2023 and is projected to grow at a CAGR of 25-27% from 2023 to 2030. The growth of this market is primarily driven by the increasing prevalence of psoriasis worldwide, advancements in the development of biosimilars, and the rising focus on reducing healthcare costs. North America and Europe currently hold a substantial market share, owing to well-established healthcare infrastructures, high patient awareness, and supportive regulatory frameworks for biosimilar approvals. However, the Asia-Pacific region is expected to witness the highest growth rate in the coming years, driven by a growing patient population, increased healthcare spending, and the rising adoption of biologics and biosimilars in emerging economies.

---

## Market Trends

1.

### Rising Demand for Cost-Effective Treatments:

Psoriasis is a lifelong condition that requires ongoing treatment, which can be costly. As biologic treatments become more expensive, biosimilars offer a more affordable alternative. This shift is driving the adoption of biosimilars, making them a key trend in psoriasis treatment.

2.

### Increasing Approval of Psoriasis Biosimilars:

Regulatory agencies like the U.S. FDA and the European Medicines Agency (EMA) have been approving biosimilars at a faster rate, which is improving patient access to effective psoriasis treatments. Many biosimilars are now available as alternatives to expensive reference biologics such as Humira (adalimumab) and Enbrel (etanercept).

3.

